Skip to content

Effects of Mulligan Mobilization in Comparison With Maitland Mobilization in Temporomandibular Joint Dysfunction.

Effects of Mulligan Mobilization in Comparison With Maitland Mobilization in Temporomandibular Joint Dysfunction

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07328269
Enrollment
30
Registered
2026-01-09
Start date
2025-09-05
Completion date
2026-01-05
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular Joint Dysfunction

Keywords

Hypomobility, Mulligan Mobilization, Maitland Mobilization

Brief summary

The temporomandibular joint dysfunction is the second most common musculoskeletal pain after back pain, causing jaw pain, restricted movement, and joint sounds. NPRS and millimeter ruler will be used for the assessment of patient. This study will compare the effects of Mulligan and Maitland mobilization, commonly used treatment, on pain and Temporomandibular joint mobility through a randomized controlled trial, involving 30 participants divided into two groups for treatment.

Detailed description

The temporomandibular joint connects the mandible to the temporal bone near the ear's tragus and plays a key role in mastication. It involves joint or muscle pain, jaw movement limitation, and joint popping sound Risk factors include trauma, bruxism, arthritis, stress, and poor posture, while diagnosis is commonly made using the DC/TMD criteria, focusing on pain and intra-articular dysfunction. Manual therapy techniques widely used to restore joint function and reduce pain. Among these, Mulligan's Mobilization combines therapist-applied glides with active patient movement, while Maitland mobilization uses graded oscillatory techniques to relieve pain and improve mobility. This study aims to compare the effects of Mulligan and Maitland mobilization on pain reduction and TMJ hypomobility in adults with TMD. A randomized controlled trial will be conducted over one year. 30 participants will be selected through purposive sampling and randomly divided into two groups. The intervention will last two weeks, comprising 06 treatment sessions. Assessments will be conducted at baseline, after the third session, and at the end of the second week. Treatment will include lateral, anterior, medial, and distraction glides, combined with Rocabado's 6x6 exercises to improve functional movement. Myofascial release for the temporalis and masseter muscles will also be applied.

Interventions

PROCEDUREMulligan Mobilization

Both Mulligan and Maitland mobilization techniques with Myofascial release of temporalis and masseter and Rocabado 6\*6 exercise program are applied over a two-week period with six sessions in total, focusing on improving TMJ mobility and reducing pain. Group A Mulligan mobilization emphasizes active patient involvement combined with therapist-applied glides, including lateral, anterior, medial, and distraction glides performed for 5-10 seconds with 3-5 repetitions per session. These techniques enhance mouth opening, lateral deviation, protrusion, and joint space while reducing stiffness and pain. And baseline treatment of myofascial release of temporalis and masseter muscle and Rocabado's 6\*6 exercise program

Group B-Maitland mobilization relies on graded oscillatory movements (Grades I-III) for 5-10 seconds with 3-5 oscillations, targeting pain relief and mobility in the pain-free range. Lower grades (I-II) are used for acute pain with gentle oscillations, while higher grades (II-III) provide moderate mobilization to improve protrusion, lateral deviation, and joint capsule mobility. And baseline treatment of myofascial release of temporalis and masseter muscle and Rocabado's 6\*6 exercise program.

Sponsors

Foundation University Islamabad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participant will just have an idea of two interventions not the one given to him/her.

Intervention model description

Participant divided into Two groups Group A recieves Mulligan Mobilization and Group B receives Maitland Mobilization with baseline treatment of myofascial release of temporalis and masseter muscle and Rocabado's 6\*6 exercise program.

Eligibility

Sex/Gender
ALL
Age
19 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

* Age 19-44 years. * Both Genders (Male and Female). * Patients diagnosed with TMJ hypomobility using the Manual Functional Analysis questionnaire based on DC/TMD criteria. * Individuals with myofascial pain, scoring above 5 on the NRS and pain upon palpation of at least two of eight masticatory and neck muscles. * Subjects with acute TMD and myofascial pain unrelated to active inflammation, infection, or recent trauma for at least six months.

Exclusion criteria

* Hypermobility of TMJs. * Pregnancy. * History of rheumatic and inflammatory diseases. * A history of temporomandibular disorders treatment within last three months. * Acute trauma or injuries of face, head or cervical spine, neurological disorders, taking medication that could affect the musculoskeletal system.

Design outcomes

Primary

MeasureTime frameDescription
Temporomandibular joint Hypomobility2 weeksMandibular movements were assessed using a millimeter ruler to measure depression (50-60 mm), protrusion (5 mm), and lateral deviation (12-15 mm). Any click sounds or deviations during movement were recorded. Jaw movements maintained upper and lower teeth contact.
Pain intensity2 weeksPain will be measured through Numeric Pain Rating Scale. The scoring for NPRS involves a scale from 0 to 10, where 0 indicates no pain. The interpretation of scores is as follows: 0 to 3 for mild pain, 4 to 6 for moderate pain, and 7 to 10 for severe pain.

Countries

Pakistan

Contacts

Primary ContactMah Noor
mahnoorbasharat33@gmail.com+92310-5351360
Backup ContactAnam Rehman, MS-OMPT
anam.rehman@fui.edu.pk+923355082299

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026